Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
4:15PM – 5:30PM

In-person registrationLive broadcast registration

Mikael Dolsten, Chief Scientific Officer & President, Worldwide Research, Development and Medical, Pfizer

Robert Bradway, Chairman & CEO, Amgen
John G. Houston, President & CEO, Arvinas
Michelle McMurry-Heath, President & CEO, BIO
Jeffrey A. Spaeder, Chief Medical and Scientific Officer, and Senior Vice President, IQVIA
Michel Vounatsos
, CEO & Director, Biogen Inc.


Where will new Drug Therapies and Vaccines come from?

Medicines science today faces a challenge on two fronts:  how to develop and personalize a vast array of new insights into the biological origins of complex non-communicable diseases – many of which promise real cures – while fighting a resurgent viral pandemic where the ability to control its severity and spread remains little better than a century ago.  Deaths worldwide from COVID-19 are likely to reach nearly 4m by the end of this year, a grim statistic that will put infectious diseases firmly back in the top ranks as a priority for drug, device and vaccines research for the duration of the decade.

Coping with these challenges will benefit from new platform technologies that rely on a systems approach to biology, which through use of computational and mathematical analysis allows for enhanced understanding of a more diverse array of cellular functions, leading in turn to a much larger number of druggable targets against disease.  Systems biology has also spurred the growth of a complementary process for drug development known as translational medicine, which seeks to leverage basic research through multidisciplinary collaborations between researchers and clinicians with the goal of quickly turning these druggable targets into therapeutic breakthroughs that work safely at the level of the individual patient.

Overall, the industry is moving from a “one disease-one target-one drug” approach to a more customized focus on novel bioactive compounds that combine multi-target properties in a single molecule or protein.   The strategy is squarely in line with the trajectory of unmet medical need, with complex conditions like cancer, stroke, neurodegenerative disorders, COPD and respiratory infections topping the World Health Organization (WHO) list of major killers to 2030.

In the drugs space, researchers will continue to build on learnings from the first wave of cellular and gene drug therapies, with multiple products now approved for clinical use; dozens more are in late stage trials or pending FDA approval.  A key area primed for future growth is allogeneic cell therapy, which seeks to expand the current process of extracting, modifying and replacing human cells with a much faster method based on manufacturing cells synthetically, in mass quantities. This would significantly expand the range and scope of these potentially curative treatments, assuming immune response complications can be resolved safely.   Cell therapy is also being applied against major chronic conditions like diabetes, where studies are underway on reversing the immune response in type one patients that results in the premature death or depletion of beta cells responsible for producing insulin in the pancreas.

Interest is also building in new therapeutic opportunities within the proteome – the map of the thousands of proteins, the building blocks of DNA, produced in the human cell. Conventional small molecule and antibody drugs can access only a small portion of proteins, which limits the potential of the proteome as a source of druggable disease targets.  A new investigatory class of small molecule drugs called protein degraders are poised to bridge the divide, by repurposing small molecules to seek out, attach and degrade the properties of disease-causing proteins, with cancer and Alzheimer’s as important beneficiaries.

Another example of the potential gains from today’s systems biology approach is in precision cardiology, where genomic data can be applied to stratify risk for individuals susceptible to coronary artery disease – currently, the number one killer worldwide – enabling health providers to save lives by catching a genetic predisposition early in life.  And in COVID-19, the potential exists to generate stem cells to replace damaged cells in the lung incurred by the acute respiratory distress syndrome that accounts for the pandemic’s high rate of mortality.

In vaccines, future therapeutic innovations are likely in delivery technologies and also in new vaccines to treat a host of conditions unrelated to communicable infections, like cancer. Surprisingly, more than 100 vaccines for therapeutic application are currently in development for various cancers, ranking second only to the number of vaccines underway to prevent infectious diseases.  In addition to a universal influenza vaccine, supported by the Bill & Melinda Gates Foundation, progress has been made on an adult vaccine for TB as well as one against HIV; one vaccine to confer immunity against the nearly two dozen strains of pneumococcal pneumonia; and protection for the respiratory syncytial virus, a persistent hazard in infants.

Likewise, the global race for a COVID-19 solution is propelling advances in vaccine design, such as the messenger mRNA technology which avoids using viral particles, thus making a mRNA vaccine both safer for patients and faster and cheaper to manufacture than the traditional live or attenuated virus model. Likewise, work is accelerating on novel non-needle vaccine delivery technologies like micro-patches that can be attached directly by the patient without specialist assistance. All these technologies are geared to making immunization cheaper, less cumbersome and more accessible in hard-to-reach areas with limited health resources.

The following group of experts, chaired by Pfizer Chief Scientific Officer and President, Worldwide Research, Development and Medical Affairs, Dr. Mikael Dolsten, will address the questions surrounding the future of therapeutics in detail, with emphasis on structural transformations in research discovery and development as well as the progress against current standard of clinical care, highlighting the real benefits to today’s – and tomorrow’s – patients.